BOCA RATON, Fla., April 26, 2011 /PRNewswire/ -- The Premier healthcare alliance, a network of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites working together to achieve high quality, cost-effective care, has awarded Sensus Healthcare, Inc., the leading provider of FDA-approved Superficial Radiotherapy committed to providing a viable treatment option for millions of skin cancer sufferers, a group purchasing agreement for the SRT-100™. Sensus was awarded a sole three-year contract for Superficial Radiotherapy with Premier Purchasing Partners L.P., the group purchasing unit of Premier, Inc. The agreement, which is in effect through April 1, 2014 extends Premier members preferred pricing on Sensus' Superficial Radiotherapy systems for treatment of basal cell and squamous cell carcinoma skin cancers.
"We are extremely pleased to partner with such a prestigious organization such as Premier and their members. We look forward to working with their healthcare professionals in establishing the SRT-100™ as the preferred choice for non-invasive skin cancer treatment," says Joe Sardano, CEO of Sensus Healthcare.
"According to experts, 50% of the booming 60+ population will be diagnosed with skin cancer. It's important for both physicians and patients to have choices for treatment. Surgery is simply not the best alternative for every patient these days," added Steve Cohen, VP Strategic Initiatives at Sensus Healthcare. "Much of our population has existing medical conditions that are better served by treating with non-invasive Photon X-Ray Therapy."
Over 2.8 million new skin cancer cases are diagnosed annually worldwide! Available for treatment of basal cell and squamous cell carcinomas, the SRT-100™ treats skin cancers, especially those requi